



7

Attorney Docket No.: 6213.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jensen et al.

Serial No.: 09/870,884

Group Art Unit: To be assigned

Filed: May 31, 2001

Examiner: To be assigned

For: Glucose Dependent Release of Insulin from Glucose Sensing Insulin Derivatives

PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))Assistant Commissioner for Patents
Washington, DC 20231

Sir:

It is respectfully requested that the time for response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed October 15, 2002, having a shortened period for reply of two (2) months, due to expire December 15, 2002, be extended for a period of one (1) month from December 15, 2002, to January 15, 2003, to permit timely filing of the Response enclosed herewith.

01/22/2003 BSAYASI1 00000105 141447 09870884

01 FC:1251 110.00 CH



Please charge the required fee estimated to be \$110.00, and any additional fees which may be required for this petition, and credit any overpayments to Novo Nordisk Pharmaceuticals, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Rosemarie R. Wilk-Orescan
Registration Number 45,220

Date: January 10, 2003

Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969



23650

PATENT TRADEMARK OFFICE